Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul;128(7):1085-1098.
doi: 10.1007/s00702-021-02336-w. Epub 2021 May 15.

Lifetime evolution of ADHD treatment

Affiliations
Review

Lifetime evolution of ADHD treatment

Federico Mucci et al. J Neural Transm (Vienna). 2021 Jul.

Abstract

Attention-deficit hyperactivity disorder (ADHD), has been traditionally considered a neurodevelopmental disorder affecting children and adolescents characterized by inattention, hyperactivity, disruptive behavior, and impulsivity. Although still debated, it is evident that ADHD is also present in adulthood, but this diagnosis is rarely carried out, mainly for the frequent comorbidity with other psychiatric and/or substance abuse disorders. Given the need to shed more light on the pharmacological treatment of ADHD, we performed a naturalistic review to review and comment on the available literature of ADHD treatment across the lifespan. Indeed, stimulants are endowed of a prompt efficacy and safety, whilst non-stimulants, although requiring some weeks to be fully effective, are useful when a substance abuse history is detected. In any case, the pharmacological management of ADHD appears to be still largely influenced by the individual experience of the clinicians. Further longitudinal studies with a careful and detailed characterization of participants across different phases of the lifespan are also required to provide relevant confirmations (or denials) regarding pharmacological treatments amongst the different age groups.

Keywords: ADHD; Lifespan management; Non-stimulants; Pharmacological treatment; Stimulants.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Abbas G, Jorgensen RA, Lindor KD (2010) Fatigue in primary biliary cirrhosis. Nat Rev Gastroenterol Hepatol 6:313–319. https://doi.org/10.1038/nrgastro.2010.62 - DOI
    1. Abela AR, Chudasama Y (2014) Noradrenergic α2A-receptor stimulation in the ventral hippocampus reduces impulsive decision-making. Psychopharmacology 231:521–531 - PubMed - DOI
    1. Adler LA, Gorny SW (2015) Pilot study of Droxidopa with Carbidopa in adults with ADHD. J Atten Disord 23(2):189–198. https://doi.org/10.1177/1087054715580393 - DOI - PubMed
    1. Adler LA, Resnick S, Kunz M, Devinsky O (1995) Open label trial of venlafaxine in adults with attention deficit disorder. Psychopharmacol Bull 31(4):785–788 - PubMed
    1. Agenzia Italiana del Farmaco (2007) Determinazione 19 aprile 2007 — Supplemento ordinario alla ‘‘Gazzetta Ufficiale, n. 95 del 24 aprile 2007 — Serie generale “Autorizzazione all’immissione in commercio della specialità medicinale per uso umano Ritalin® e “Autorizzazione all’immissione in commercio della specialità medicinale per uso umano Strattera®. https://www.gazzettaufficiale.it/atto/serie_generale/caricaDettaglioAtto... . Accessed 31st Aug 2020

MeSH terms

Substances

LinkOut - more resources